Holen Sie sich die Stockscreener-App
12.79
4.62%
-0.62
Handel nachbörslich:
12.85
0.06
+0.47%
Schlusskurs vom Vortag:
$13.41
Offen:
$13.14
24-Stunden-Volumen:
42,551
Relative Volume:
0.01
Marktkapitalisierung:
$13.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.13M
KGV:
-0.2237
EPS:
-57.1626
Netto-Cashflow:
$-2.63M
1W Leistung:
+0.31%
1M Leistung:
+19.31%
6M Leistung:
+198.85%
1J Leistung:
-99.45%
1-Tages-Spanne:
$12.53
$13.25
1-Wochen-Bereich:
$11.30
$13.97
52-Wochen-Spanne:
$2.88
$2,550.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Vergleichen Sie PLRZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
12.79 | 13.97M | 0 | -1.13M | -2.63M | -57.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Is Polyrizon Ltd. stock undervalued vs historical averagesNew Releases Roundup & what to check before ordering - ulpravda.ru
Can Polyrizon Ltd. stock rebound after recent weaknessPortfolio Gains Report & Technical Pattern Recognition Alerts - ulpravda.ru
Why Polyrizon Ltd. stock is favored by top institutions2025 Winners & Losers & Fast Moving Trade Plans - ulpravda.ru
Polyrizon expects Nasarix introduction aligned with clinical progress - MarketScreener
Polyrizon names allergy blocker product NASARIX - Investing.com
Polyrizon Brands PL-14 Intranasal Allergy Blocker as NASARIX™ - TipRanks
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™ - The Manila Times
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX - Bluefield Daily Telegraph
NASARIX: a new nasal spray brand designed to shield against allergens - Stock Titan
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Polyrizon’s PL-14 shows strong pre-clinical allergen-blocking advantage over standard nasal barrier - MSN
Polyrizon announces in-vitro results for PL-16 Viral Blocker - MSN
Polyrizon stock rises after positive pre-clinical allergy blocker results By Investing.com - Investing.com Nigeria
Polyrizon Announces Positive Data From PL-14 Allergy Blocker Formulation Study - Nasdaq
Polyrizon’s nasal allergy blocker outperforms standard in lab study By Investing.com - Investing.com South Africa
Polyrizon’s PL-14 Shows Strong Pre-Clinical Allergen-Blocking Advantage Over Standard Nasal Barrier - TipRanks
Polyrizon’s nasal allergy blocker outperforms standard in lab study - Investing.com India
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator - The Manila Times
Lab test hints at new nasal barrier to block dust mite allergy triggers - Stock Titan
Polyrizon submits pre-request to FDA for nasal spray against flu - Investing.com Nigeria
Polyrizon submits pre-request to FDA for nasal spray against flu By Investing.com - Investing.com South Africa
Polyrizon stock rises on FDA submission for PL-16 viral blocker - Investing.com Australia
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated - The Manila Times
Could a simple nasal spray add a drug-free layer of flu protection? - Stock Titan
Polyrizon (PLRZ) Stock Analysis Report | Financials & Insights - Benzinga
Polyrizon reports mucoadhesion results for intranasal naloxone hydrogel - MSN
Polyrizon Ltd. to Explore Investment Opportunities in Revenue-Generating Real Assets - MarketScreener
Polyrizon to explore investments in revenue-generating assets By Investing.com - Investing.com Nigeria
Polyrizon to pursue revenue-generating real assets while advancing intranasal biotech pipeline - MSN
Polyrizon stock rises as company explores revenue-generating investments By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon to explore investment in revenue-generating real assets - marketscreener.com
Polyrizon to Pursue Revenue-Generating Real Assets While Advancing Intranasal Biotech Pipeline - TipRanks
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet - The Manila Times
Biotech with no debt looks beyond the lab to buy real assets - Stock Titan
Polyrizon completes manufacturing upscaling milestone for nasal spray platform - MSN
Top Medical Stocks To Keep An Eye OnDecember 2nd - MarketBeat
What risks investors should watch in Polyrizon Ltd. stockPortfolio Performance Report & Fast Gain Stock Trading Tips - moha.gov.vn
Biotech alert: Searches spiking for these stocks today - MSN
Polyrizon Achieves Key Manufacturing Milestone for Nasal Spray Platform - MSN
Polyrizon completes FDA pre-submission meeting for PL-14 nasal spray - MSN
Polyrizon unveils promising results for intranasal naloxone hydrogel - MSN
Aug Drivers: What risks investors should watch in Polyrizon Ltd. stock2025 Growth vs Value & Capital Protection Trade Alerts - Улправда
Polyrizon submits pre-request for designation to FDA for PL-16 viral blocker - marketscreener.com
Polyrizon Files FDA Pre-Request for Designation of PL-16 Intranasal Viral Blocker - TipRanks
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):